All In Biotech

Drug Trial Radar · NCT05310422

Safety Study of Tivanisiran to Treat Dry Eye

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Mar 24, 2022

Primary completion

Oct 11, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Sylentis, S.A.Industry
Sponsor type
Industry
First posted
Apr 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).

Conditions

  • Dry Eye Disease

Interventions

  • Tivanisiran sodium ophthalmic solutionDrug

    1 drop in the affected eye(s) once daily

  • Vehicle ophthalmic solutionDrug

    1 drop in the affected eye(s) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Subjects With Ocular and Non-ocular Treatment Emergent Adverse Events (TEAEs) for 1 YearTime frame: 1 year

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Sylentis Investigative Site

    Chandler, Arizona

  • Sylentis Investigative Site

    Phoenix, Arizona

  • FYDES Investigative Site

    Glendale, California

  • Sylentis Investigative Site

    Hemet, California

  • Sylentis Investigative Site

    Los Angeles, California

  • Sylentis Investigative Site

    Murrieta, California

  • Sylentis Investigative Site

    Newport Beach, California

  • FYDES Investigative Site

    Delray Beach, Florida

  • FYDES Investigative Site

    Jacksonville, Florida

  • Sylentis Investigative Site

    Largo, Florida

  • Sylentis Investigative Site

    Morrow, Georgia

  • Sylentis Investigative Site

    Fraser, Michigan

  • Sylentis Investigative Site

    Kansas City, Missouri

  • FYDES Investigative Site

    St Louis, Missouri

  • Sylentis Investigative Site

    Washington, Missouri

  • Sylentis Investigative Site

    Rochester, New York

  • Sylentis Investigative Site

    Asheville, North Carolina

  • Sylentis Investigative Site

    Garner, North Carolina

  • Sylentis Investigative Site

    Cranberry Township, Pennsylvania

  • Sylentis Investigative Site

    Rapid City, South Dakota

  • Sylentis Investigative Site

    Memphis, Tennessee

  • Sylentis Investigative Site

    Austin, Texas

  • FYDES Investigative Site

    El Paso, Texas

  • Sylentis Investigative Site

    San Antonio, Texas

  • Sylentis Investigative Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.